Biological and biochemical characterization of a factor produced spontaneously by adherent cells of human immunodeficiency virus-infected patients inhibiting interleukin-2 receptor alpha chain (Tac) expression on normal T cells
Adherent cells from human immunodeficiency virus (HIV)-infected subjects but not from normal blood donors, patients with Gram-positive or -negative bacteremia, active tuberculosis, toxoplasmosis, pulmonary aspergillosis, and cytomegalovirus infection produce spontaneously an activity which inhibits...
Saved in:
Published in | The Journal of clinical investigation Vol. 87; no. 6; pp. 2048 - 2055 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Ann Arbor, MI
American Society for Clinical Investigation
01.06.1991
|
Subjects | |
Online Access | Get full text |
ISSN | 0021-9738 |
DOI | 10.1172/JCI115235 |
Cover
Abstract | Adherent cells from human immunodeficiency virus (HIV)-infected subjects but not from normal blood donors, patients with Gram-positive or -negative bacteremia, active tuberculosis, toxoplasmosis, pulmonary aspergillosis, and cytomegalovirus infection produce spontaneously an activity which inhibits alpha chain of interleukin-2 (Tac) expression and interleukin 2 (IL-2) production by normal activated T cells and IL-2 production by these cells. A similar biologic activity was detected in culture supernatants of in vitro HIV-I-infected normal adherent and leukemic U937 cells. Tac-inhibitory activity is not cytotoxic and it could be detected in serum-free conditioned media. Recombinant granulocyte/macrophage colony-stimulating factor and phorbol myristate acetate stimulation of patients' and normal adherent cells did not enhance specifically the production of the Tac inhibitor. Biologically active conditioned media did not contain infectious virus as well as secreted p24, gp120 viral proteins; the biologic activity could not be abolished by anti-p24, anti-gp120, and anti-nef monoclonal antibodies or human purified polyclonal anti-HIV IgG. Gel filtration of conditioned media followed by anion exchange chromatography resulted in a 1,200-fold degree of purification and revealed that the biologically active molecule was cationic. Sodium dodecyl sulfate polyacrylamide gel electrophoresis of this fraction and gel elution of the proteins showed that the biologic activity was associated with a 29-kD protein which was distinct from alpha- or gamma-interferon, tumor necrosis factor-alpha, and prostaglandin E2. The above findings demonstrate the production of inhibitory factor(s) during HIV infection, which might be involved in the pathogenesis of the patients' immune defect. |
---|---|
AbstractList | Adherent cells from human immunodeficiency virus (HIV)-infected subjects but not from normal blood donors, patients with Gram-positive or -negative bacteremia, active tuberculosis, toxoplasmosis, pulmonary aspergillosis, and cytomegalovirus infection produce spontaneously an activity which inhibits alpha chain of interleukin-2 (Tac) expression and interleukin 2 (IL-2) production by normal activated T cells and IL-2 production by these cells. A similar biologic activity was detected in culture supernatants of in vitro HIV-I-infected normal adherent and leukemic U937 cells. Tac-inhibitory activity is not cytotoxic and it could be detected in serum-free conditioned media. Recombinant granulocyte/macrophage colony-stimulating factor and phorbol myristate acetate stimulation of patients' and normal adherent cells did not enhance specifically the production of the Tac inhibitor. Biologically active conditioned media did not contain infectious virus as well as secreted p24, gp120 viral proteins; the biologic activity could not be abolished by anti-p24, anti-gp120, and anti-nef monoclonal antibodies or human purified polyclonal anti-HIV IgG. Gel filtration of conditioned media followed by anion exchange chromatography resulted in a 1,200-fold degree of purification and revealed that the biologically active molecule was cationic. Sodium dodecyl sulfate polyacrylamide gel electrophoresis of this fraction and gel elution of the proteins showed that the biologic activity was associated with a 29-kD protein which was distinct from alpha- or gamma-interferon, tumor necrosis factor-alpha, and prostaglandin E2. The above findings demonstrate the production of inhibitory factor(s) during HIV infection, which might be involved in the pathogenesis of the patients' immune defect. Adherent cells from human immunodeficiency virus (HIV)-infected subjects but not from normal blood donors, patients with Gram-positive or -negative bacteremia, active tuberculosis, toxoplasmosis, pulmonary aspergillosis, and cytomegalovirus infection produce spontaneously an activity which inhibits alpha chain of interleukin-2 (Tac) expression and interleukin 2 (IL-2) production by normal activated T cells and IL-2 production by these cells. The above findings demonstrate the production of inhibitory factor(s) during HIV infection, which might be involved in the pathogenesis of the patients' immune defect. Adherent cells from human immunodeficiency virus (HIV)-infected subjects but not from normal blood donors, patients with Gram-positive or -negative bacteremia, active tuberculosis, toxoplasmosis, pulmonary aspergillosis, and cytomegalovirus infection produce spontaneously an activity which inhibits alpha chain of interleukin-2 (Tac) expression and interleukin 2 (IL-2) production by normal activated T cells and IL-2 production by these cells. A similar biologic activity was detected in culture supernatants of in vitro HIV-I-infected normal adherent and leukemic U937 cells. Tac-inhibitory activity is not cytotoxic and it could be detected in serum-free conditioned media. Recombinant granulocyte/macrophage colony-stimulating factor and phorbol myristate acetate stimulation of patients' and normal adherent cells did not enhance specifically the production of the Tac inhibitor. Biologically active conditioned media did not contain infectious virus as well as secreted p24, gp120 viral proteins; the biologic activity could not be abolished by anti-p24, anti-gp120, and anti-nef monoclonal antibodies or human purified polyclonal anti-HIV IgG. Gel filtration of conditioned media followed by anion exchange chromatography resulted in a 1,200-fold degree of purification and revealed that the biologically active molecule was cationic. Sodium dodecyl sulfate polyacrylamide gel electrophoresis of this fraction and gel elution of the proteins showed that the biologic activity was associated with a 29-kD protein which was distinct from alpha- or gamma-interferon, tumor necrosis factor-alpha, and prostaglandin E2. The above findings demonstrate the production of inhibitory factor(s) during HIV infection, which might be involved in the pathogenesis of the patients' immune defect.Adherent cells from human immunodeficiency virus (HIV)-infected subjects but not from normal blood donors, patients with Gram-positive or -negative bacteremia, active tuberculosis, toxoplasmosis, pulmonary aspergillosis, and cytomegalovirus infection produce spontaneously an activity which inhibits alpha chain of interleukin-2 (Tac) expression and interleukin 2 (IL-2) production by normal activated T cells and IL-2 production by these cells. A similar biologic activity was detected in culture supernatants of in vitro HIV-I-infected normal adherent and leukemic U937 cells. Tac-inhibitory activity is not cytotoxic and it could be detected in serum-free conditioned media. Recombinant granulocyte/macrophage colony-stimulating factor and phorbol myristate acetate stimulation of patients' and normal adherent cells did not enhance specifically the production of the Tac inhibitor. Biologically active conditioned media did not contain infectious virus as well as secreted p24, gp120 viral proteins; the biologic activity could not be abolished by anti-p24, anti-gp120, and anti-nef monoclonal antibodies or human purified polyclonal anti-HIV IgG. Gel filtration of conditioned media followed by anion exchange chromatography resulted in a 1,200-fold degree of purification and revealed that the biologically active molecule was cationic. Sodium dodecyl sulfate polyacrylamide gel electrophoresis of this fraction and gel elution of the proteins showed that the biologic activity was associated with a 29-kD protein which was distinct from alpha- or gamma-interferon, tumor necrosis factor-alpha, and prostaglandin E2. The above findings demonstrate the production of inhibitory factor(s) during HIV infection, which might be involved in the pathogenesis of the patients' immune defect. |
Author | Cibert, C Jasmin, C Tsilivakos, V Georgoulias, V Bertoli, A M Ammar, A |
AuthorAffiliation | Unité d'Oncogénèse Appliquée, Institut National de la Santé et de la Recherche Médicale Unité 268, Hôpital Paul Brousse, Villejuif, France |
AuthorAffiliation_xml | – name: Unité d'Oncogénèse Appliquée, Institut National de la Santé et de la Recherche Médicale Unité 268, Hôpital Paul Brousse, Villejuif, France |
Author_xml | – sequence: 1 givenname: A surname: Ammar fullname: Ammar, A – sequence: 2 givenname: C surname: Cibert fullname: Cibert, C – sequence: 3 givenname: A M surname: Bertoli fullname: Bertoli, A M – sequence: 4 givenname: V surname: Tsilivakos fullname: Tsilivakos, V – sequence: 5 givenname: C surname: Jasmin fullname: Jasmin, C – sequence: 6 givenname: V surname: Georgoulias fullname: Georgoulias, V |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=5413712$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/1904071$$D View this record in MEDLINE/PubMed |
BookMark | eNqFUstu1DAUzaKotIUFH4DkBUJ0EWo7jpMsWJRRgaJKbIZ15DjXkwuJHeykYvjd_gjOzGh4CImVH_ece86x73lyYp2FJHnG6GvGCn71cXXLWM6z_CQ5o5SztCqy8nFyHsIXSpkQuThNTllFBS3YWfLwFl3vNqhVT5RtSYNOdzDszrpTXukJPP5QEzpLnCGKmHjlPBm9a2cNLQmjs5Oy4ObQb0mzJartwIOdiIa-DwupmwdlCQ7DbF0LBjWC1Vtyj34OKVoDUaQlYxSJtEDQdtjghHYTt1G-h_kr2pQTDxrGRVz1Y6cWf2jJq7XSlwS-jx5C2Lm0xDo_xADrvYUnySOj-gBPD-tF8vndzXr1Ib379P52dX2XasGrKZUyZ7It20azBrThbVMInkFTlWWeFbQCQcuspDIzSmS8KDIuJa-MqUwDtDSQXSRv9n3HuRmg1TGMV309ehyU39ZOYf1nxWJXb9x9zStZSRb5Lw98777NEKZ6wLAk2L9uXdK84oUs_wtkkgpOpYjA5787Olo5fH-svzjUVYg_bryyGsMRlguWFYxH2OUepr0LwYP51YjWy9DVx6GL2Ku_sBqn3fjEyNj_g_ETUW3hnw |
CODEN | JCINAO |
CitedBy_id | crossref_primary_10_1016_0925_4439_92_90104_U crossref_primary_10_1016_S0248_8663_97_84392_5 crossref_primary_10_1111_j_1749_6632_1993_tb35912_x crossref_primary_10_1007_BF02918280 crossref_primary_10_1046_j_1537_2995_1997_37197176953_x |
ContentType | Journal Article |
Copyright | 1992 INIST-CNRS |
Copyright_xml | – notice: 1992 INIST-CNRS |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7T5 7U9 H94 7X8 5PM |
DOI | 10.1172/JCI115235 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Immunology Abstracts Virology and AIDS Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE AIDS and Cancer Research Abstracts MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EndPage | 2055 |
ExternalDocumentID | PMC296961 1904071 5413712 10_1172_JCI115235 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -~X .55 .GJ 29K 2WC 3O- 53G 5GY 5RE 8F7 AAWTL AAYXX ABOCM ACGFO ACIHN ACNCT ACPRK ADBBV AEAQA AENEX AFFNX AHMBA AI. ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION CS3 D-I DIK DU5 E3Z EBS EJD EMB F5P FRP GROUPED_DOAJ GX1 HYE H~9 IAO IEA IHR INH IOF IPO J5H KQ8 L7B M1P MVM N4W OK1 OVT P2P P6G RPM TEORI TR2 TVE VH1 VVN W2D WH7 WOQ WOW X7M YOC ZGI ZXP ZY1 .XZ 08G 08P 354 36B 5RS 7RV 7X7 88E 8AO 8FE 8FH 8FI 8FJ 8R4 8R5 AAKAS ABPMR ABUWG ADZCM AFCHL AFKRA ASPBG AVWKF AZFZN BBNVY BCR BCU BEC BENPR BHPHI BKEYQ BLC BPHCQ BVXVI CCPQU EBD EMOBN EX3 FEDTE FYUFA HCIFZ HMCUK HVGLF IHW IOV IQODW ISR ITC LK8 M5~ M7P NAPCQ OBH OCB ODZKP OFXIZ OGEVE OHH OHT OVD OVIDX PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO Q2X S0X SJFOW SV3 UHU UKHRP XSB YFH YHG YKV ~H1 3V. 88A AAYOK CGR CUY CVF ECM EIF INR M0L NPM PKN 7T5 7U9 H94 7X8 5PM |
ID | FETCH-LOGICAL-c429t-66516d8dbc1becf2db7423eb98853709e40838063fa43277326629ff9fbe08fe3 |
ISSN | 0021-9738 |
IngestDate | Thu Aug 21 14:02:46 EDT 2025 Thu Sep 04 20:13:49 EDT 2025 Fri Sep 05 09:59:22 EDT 2025 Wed Feb 19 01:12:21 EST 2025 Mon Jul 21 09:12:52 EDT 2025 Tue Jul 01 01:43:32 EDT 2025 Thu Apr 24 23:06:56 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | Infection Human Immunopathology Pathology Interleukin 2 Viral disease Exploration AIDS Receiver Molecular biology Adhesion Cell |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c429t-66516d8dbc1becf2db7423eb98853709e40838063fa43277326629ff9fbe08fe3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
OpenAccessLink | http://www.jci.org/articles/view/115235/files/pdf |
PMID | 1904071 |
PQID | 16042064 |
PQPubID | 23462 |
PageCount | 8 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_296961 proquest_miscellaneous_80592768 proquest_miscellaneous_16042064 pubmed_primary_1904071 pascalfrancis_primary_5413712 crossref_primary_10_1172_JCI115235 crossref_citationtrail_10_1172_JCI115235 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 1900 |
PublicationDate | 1991-06-01 |
PublicationDateYYYYMMDD | 1991-06-01 |
PublicationDate_xml | – month: 06 year: 1991 text: 1991-06-01 day: 01 |
PublicationDecade | 1990 |
PublicationPlace | Ann Arbor, MI |
PublicationPlace_xml | – name: Ann Arbor, MI – name: United States |
PublicationTitle | The Journal of clinical investigation |
PublicationTitleAlternate | J Clin Invest |
PublicationYear | 1991 |
Publisher | American Society for Clinical Investigation |
Publisher_xml | – name: American Society for Clinical Investigation |
References | 6606682 - J Immunol Methods. 1983 Dec 16;65(1-2):55-63 6235286 - J Immunol. 1984 Sep;133(3):1313-7 2967332 - J Immunol. 1988 Jun 15;140(12):4245-52 2417965 - Int J Cancer. 1986 Feb 15;37(2):247-53 6096719 - Nature. 1984 Dec 20-1985 Jan 2;312(5996):763-7 3485456 - Blood. 1986 Apr;67(4):1063-9 7114072 - Am J Med. 1982 Aug;73(2):171-8 2995487 - J Immunol. 1985 Nov;135(5):3151-62 6328662 - Science. 1984 Jul 6;225(4657):66-9 3663934 - Blood. 1987 Nov;70(5):1267-72 6605980 - J Clin Invest. 1983 Dec;72(6):2072-81 6189183 - Science. 1983 May 20;220(4599):868-71 2665081 - Science. 1989 Jul 21;245(4915):305-8 6318629 - Ann Intern Med. 1984 Jan;100(1):92-106 3114567 - Leuk Res. 1987;11(8):753-60 3011909 - J Immunol. 1986 Jul 1;137(1):323-9 2865566 - Lancet. 1985 Nov 16;2(8464):1083-6 3874021 - Clin Exp Immunol. 1985 May;60(2):285-93 2965728 - J Immunol. 1988 Apr 15;140(8):2639-44 3003749 - Proc Natl Acad Sci U S A. 1986 Feb;83(3):772-6 3349526 - Cell. 1988 Apr 8;53(1):45-53 3490518 - J Immunol Methods. 1986 Nov 6;93(2):157-65 6218186 - J Clin Invest. 1983 Feb;71(2):296-300 2422213 - J Clin Invest. 1986 May;77(5):1712-5 958392 - Nature. 1976 Jul 29;262(5567):401-2 2786762 - Cell Immunol. 1989 Jul;121(2):336-48 3013342 - Blood. 1986 Jul;68(1):281-4 5432063 - Nature. 1970 Aug 15;227(5259):680-5 3281762 - Cell Immunol. 1988 Apr 1;112(2):414-24 3037522 - Proc Natl Acad Sci U S A. 1987 Jul;84(13):4601-5 3871770 - J Biol Chem. 1985 Feb 25;260(4):2345-54 239056 - J Immunol. 1975 Jul;115(1):230-3 2523711 - AIDS. 1989 Mar;3(3):125-33 4128882 - Anal Biochem. 1973 Dec;56(2):502-14 6200935 - Science. 1984 May 4;224(4648):497-500 6609030 - Clin Exp Immunol. 1984 Apr;56(1):14-7 2563266 - J Clin Invest. 1989 Feb;83(2):610-5 |
References_xml | – reference: 6189183 - Science. 1983 May 20;220(4599):868-71 – reference: 6605980 - J Clin Invest. 1983 Dec;72(6):2072-81 – reference: 2523711 - AIDS. 1989 Mar;3(3):125-33 – reference: 2422213 - J Clin Invest. 1986 May;77(5):1712-5 – reference: 2563266 - J Clin Invest. 1989 Feb;83(2):610-5 – reference: 3011909 - J Immunol. 1986 Jul 1;137(1):323-9 – reference: 3874021 - Clin Exp Immunol. 1985 May;60(2):285-93 – reference: 5432063 - Nature. 1970 Aug 15;227(5259):680-5 – reference: 2665081 - Science. 1989 Jul 21;245(4915):305-8 – reference: 2995487 - J Immunol. 1985 Nov;135(5):3151-62 – reference: 6235286 - J Immunol. 1984 Sep;133(3):1313-7 – reference: 2417965 - Int J Cancer. 1986 Feb 15;37(2):247-53 – reference: 239056 - J Immunol. 1975 Jul;115(1):230-3 – reference: 3114567 - Leuk Res. 1987;11(8):753-60 – reference: 958392 - Nature. 1976 Jul 29;262(5567):401-2 – reference: 3037522 - Proc Natl Acad Sci U S A. 1987 Jul;84(13):4601-5 – reference: 2967332 - J Immunol. 1988 Jun 15;140(12):4245-52 – reference: 2965728 - J Immunol. 1988 Apr 15;140(8):2639-44 – reference: 3003749 - Proc Natl Acad Sci U S A. 1986 Feb;83(3):772-6 – reference: 6318629 - Ann Intern Med. 1984 Jan;100(1):92-106 – reference: 2786762 - Cell Immunol. 1989 Jul;121(2):336-48 – reference: 7114072 - Am J Med. 1982 Aug;73(2):171-8 – reference: 6606682 - J Immunol Methods. 1983 Dec 16;65(1-2):55-63 – reference: 6200935 - Science. 1984 May 4;224(4648):497-500 – reference: 6328662 - Science. 1984 Jul 6;225(4657):66-9 – reference: 4128882 - Anal Biochem. 1973 Dec;56(2):502-14 – reference: 3349526 - Cell. 1988 Apr 8;53(1):45-53 – reference: 3281762 - Cell Immunol. 1988 Apr 1;112(2):414-24 – reference: 3013342 - Blood. 1986 Jul;68(1):281-4 – reference: 3485456 - Blood. 1986 Apr;67(4):1063-9 – reference: 6096719 - Nature. 1984 Dec 20-1985 Jan 2;312(5996):763-7 – reference: 3490518 - J Immunol Methods. 1986 Nov 6;93(2):157-65 – reference: 3871770 - J Biol Chem. 1985 Feb 25;260(4):2345-54 – reference: 6218186 - J Clin Invest. 1983 Feb;71(2):296-300 – reference: 3663934 - Blood. 1987 Nov;70(5):1267-72 – reference: 6609030 - Clin Exp Immunol. 1984 Apr;56(1):14-7 – reference: 2865566 - Lancet. 1985 Nov 16;2(8464):1083-6 |
SSID | ssj0014454 |
Score | 1.4529059 |
Snippet | Adherent cells from human immunodeficiency virus (HIV)-infected subjects but not from normal blood donors, patients with Gram-positive or -negative bacteremia,... |
SourceID | pubmedcentral proquest pubmed pascalfrancis crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 2048 |
SubjectTerms | Biological and medical sciences Cell Adhesion Dinoprostone - pharmacology Granulocyte-Macrophage Colony-Stimulating Factor - pharmacology HIV Infections - physiopathology Humans Immunopathology Interferon Type I - pharmacology Interferon-gamma - pharmacology Medical sciences Molecular Weight Opportunistic Infections - immunology Proteins - chemistry Proteins - pharmacology Receptors, Interleukin-2 - drug effects Retroviridae Proteins - pharmacology Tetradecanoylphorbol Acetate - pharmacology Tumor Necrosis Factor-alpha - pharmacology |
Title | Biological and biochemical characterization of a factor produced spontaneously by adherent cells of human immunodeficiency virus-infected patients inhibiting interleukin-2 receptor alpha chain (Tac) expression on normal T cells |
URI | https://www.ncbi.nlm.nih.gov/pubmed/1904071 https://www.proquest.com/docview/16042064 https://www.proquest.com/docview/80592768 https://pubmed.ncbi.nlm.nih.gov/PMC296961 |
Volume | 87 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLXGkBASQnxNFBhcIR6GpkCSponzWKZN29jGSyr1LYoTW4020mltEdtf5GfwR7jXTpymK-JDaqMqcR0r98S-1z73mLF3uQhyHvC-4wrBnSCPMicLZO4oHmVF2Jderrk5p2fh4Sg4Hg_GGxs_llhLi7n4kN-szSv5H6viObQrZcn-g2VtpXgCf6N98YgWxuNf2dhsJGnz_UVJ21-Z_P_cCjHfWKcwq3fXIVJWsaCFf-LHoncoMfy_uCZPNCsmUus10YS-ZnmYTfxKSiOZFpL0JnSy5rfyajFzDJULK6rlWYncNSlFOTeZMsQWlYvzsnL8XexZ5SXdXGf3UvtKwh1PspxmJuT3mpFb0fJFRZ70xW5imrHsQLepbNqJtomdZasX0hILhl9r_riF6Z4WE-7MDn_CE1OTJD5s54aTWUmLZOfTZrf4ZnKkS-KyyQqeE0dGQKbp8OsRvrzde7tG9fP2sBKRTO3x3hH6z76RV-lKd599SQ9GJydpsj9O7rC7fhQZzsDRZ7ukFQSDWhLctKiWucKqP9qKO87Rg8tshg9QmQ1W1kVAq0TeJc8oecQe1taAocHnY7Yhqyfs3mlN2njKfrYwBYQpLMEUVmEKUwUZGJhCA1PowBTENTQwBY0P-pOGKazCFLowhQam0MIUOjCFBqagYQoaprCDIH0PLUQBPwaikJgmPGOjg_1k79Cp9xZxcvTA5k4YDryw4IXIPezFlF8IoixIEXP0XyM3lgHGJhz9d5UFfTQnRjmhHysVKyFdrmR_i21W00o-Z9B3lVuEnsDIKggyHgrVj1UsY4Hfgkeqx3Yao6Z5LbxP-79cpDoAj_zU2r_H3tqil0ZtZl2h7Q4ybMkBOqSR5_fYmwYpKY4V9BSMhVIvxCEaY5Dfl-AYbflRyHtsyyCrbUbs0txPj4UdyNnrJFPfvVKVEy1X75MAl_fij_d8ye63r_Artjm_Wsht9Pjn4rV-k34BIOEUTA |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Biological+and+biochemical+characterization+of+a+factor+produced+spontaneously+by+adherent+cells+of+human+immunodeficiency+virus-infected+patients+inhibiting+interleukin-2+receptor+alpha+chain+%28Tac%29+expression+on+normal+T+cells&rft.jtitle=The+Journal+of+clinical+investigation&rft.au=Ammar%2C+A&rft.au=Cibert%2C+C&rft.au=Bertoli%2C+A+M&rft.au=Tsilivakos%2C+V&rft.date=1991-06-01&rft.issn=0021-9738&rft.volume=87&rft.issue=6&rft.spage=2048&rft_id=info:doi/10.1172%2FJCI115235&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-9738&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-9738&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-9738&client=summon |